Evan David Seigerman
Stock Analyst at BMO Capital
(3.74)
# 913
Out of 5,182 analysts
55
Total ratings
54.17%
Success rate
8.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $120 → $100 | $71.41 | +40.04% | 2 | Feb 17, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $117.10 | +11.02% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $749.41 | +13.42% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $350.16 | +6.24% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $40.46 | +13.69% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $2.07 | +431.40% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $203.71 | +17.81% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $27.74 | -6.27% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.09 | +26.75% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $10.81 | -7.49% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $48.22 | +107.38% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $27.52 | +30.81% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $7.22 | -58.45% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $919.90 | -56.95% | 1 | Sep 6, 2022 |
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120 → $100
Current: $71.41
Upside: +40.04%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $117.10
Upside: +11.02%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $749.41
Upside: +13.42%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $350.16
Upside: +6.24%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $40.46
Upside: +13.69%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $2.07
Upside: +431.40%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $203.71
Upside: +17.81%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $27.74
Upside: -6.27%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.09
Upside: +26.75%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $10.81
Upside: -7.49%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $48.22
Upside: +107.38%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $27.52
Upside: +30.81%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $7.22
Upside: -58.45%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $919.90
Upside: -56.95%